TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00042679
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01998919
Drug: carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5 x AUC iv Day 1 of each 4.week cycle, 6 cycles; or cisplatin
Study: NCT02643732
Drug: Methylphenidate (overencapsulated)
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10mg (1 capsule) methylphenidate (standard release) twice daily, increased to 20mg (2 capsules) twice daily after 2 weeks. The drug can be down-titrated in the event of side effects, although re-uptitration is not allowed even if the side effects resolve on the lower dose.
Study: NCT03696901
Drug: Xydalba
DrugBank: Dalbavancin (DB06219)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Information will be recorded about Xydalba administration (e.g. dose(s), number of infusions, length of infusions, dates or schedule of administration, sites of administration \[e.g. hospital, ICU\]), and reason for discontinuation, including response to treatment to assess whether the patient was clinically improving when Xydalba was discontinued
Study: NCT04190004
Drug: Vasopressins
Normalized name: Vasopressin
DrugBank: Vasopressin (DB00067)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 40 International units of vasopressin or placebo will be given intra-nasally. The order of the administration will be counterbalanced
Study: NCT01423916
Drug: OPC-34712 (4mg)
Normalized name: OPC-14523
DrugBank: OPC-14523 (DB05422)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arms assigned to this intervention receive 4mg.
Study: NCT01423916
Drug: Moxifloxacin
Normalized name: Moxifloxacin
DrugBank: Moxifloxacin (DB00218)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Arms assigned to this intervention will receive 400mg.
Study: NCT01423916
Drug: OPC-34712 (12mg)
Normalized name: OPC-14523
DrugBank: OPC-14523 (DB05422)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arms assigned to this intervention receive 12mg.
Study: NCT02976441
Drug: Temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01020097
Drug: fluorine F18 EF5
Normalized name: fluorine
DrugBank: Fluorine F-18 (DB13134)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT01471210
Drug: Urelumab (BMS-663513)
Normalized name: Avelumab
DrugBank: Urelumab (DB12077)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT04378231
Drug: Amoxicillin-Clavulanate 200 Mg-28.5 Mg Oral dry suspension
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: dry suspension of amoxicillin clavulanate potassium
Study: NCT00652886
Drug: Oxandrolone
Normalized name: Oxandrolone
DrugBank: Oxandrolone (DB00621)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablets, 10mg, single-dose
Study: NCT00652886
Drug: Oxandrin
Normalized name: Oxandrin
DrugBank: Oxandrolone (DB00621)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: tablets, 10mg, single-dose
Study: NCT03313336
Drug: EMLA current reference patch
Normalized name: lidocaine / prilocaine Medicated Patch [EMLA]
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EMLA current Reference Patch, containing the active ingredients lidocaine base 25 mg/g and prilocaine base 25 mg/g in an oil-in-water emulsion saturating the absorbent cellulose disc.
Study: NCT03695822
Drug: Mirabegron 25mg
Normalized name: MIRABEGRON 25MG SA TAB
DrugBank: Mirabegron (DB08893)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The aim of this study is to elucidate the impact of mirabegron on psychological distress, bladder blood flow and c reactive protein.
Study: NCT00518297
Drug: Raltegravir
Normalized name: Raltegravir
DrugBank: Raltegravir (DB06817)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tablet, Oral, 400 mg, twice daily for 5 Days
Study: NCT00518297
Drug: Atazanavir
Normalized name: Atazanavir
DrugBank: Atazanavir (DB01072)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Capsule, Oral, 300 mg, twice daily for 7 Days
Study: NCT00518297
Drug: Atazanavir + Raltegravir
DrugBank: Atazanavir (DB01072)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Capsule/Tablet, Oral, 300/400, twice daily for 14 Days
Study: NCT01088022
Drug: Aprepitant, Palonosetron, Dexamethasone
DrugBank: Palonosetron (DB00377)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Aprepitant 125-mg capsule 80-mg capsule 80-mg capsule Palonosetron 0.25 mg i.v. Dexamethasone 8 mg i.v. 8 mg os 8 mg os
Study: NCT01088022
Drug: Placebo, Palonosetron, Dexamethasone
DrugBank: Palonosetron (DB00377)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Aprepitant 125-mg placebo capsule 80-mg placebo capsule 80-mg placebo capsule Palonosetron 0.25 mg i.v. Dexamethasone 8 mg i.v. 8 mg os 8 mg os
Study: NCT01079936
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Beginning dose level 25 mg by mouth (PO) on Days -8 to -2
Study: NCT01079936
Drug: Melphalan
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dose level 100 mg/m2 by vein (IV) Days -3 and -2 over 30 minutes infusion
Study: NCT00624754
Drug: Formoterol/Budesonide
DrugBank: Formoterol (DB00983)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide/Formoterol 400/12: 800 µg b.i.d for 1 month
Study: NCT02522650
Drug: Triamterene
Normalized name: Triamterene
DrugBank: Triamterene (DB00384)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50mg twice a day for 8 weeks
Study: NCT01992380
Drug: Flortaucipir F18
Normalized name: Flortaucipir
DrugBank: Flortaucipir (DB15033)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV injection, 370 MBq (10 mCi), two doses up to four weeks apart
Study: NCT05418036
Drug: Sotalol Oral Tablet
Normalized name: sotalol Oral Tablet
DrugBank: Sotalol (DB00489)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dose of sotalol is prescribed by the attending physician. Accepted for this protocol when the dose is no greater than 160 mg/day
Study: NCT00626028
Drug: Oxygen
Normalized name: Oxygen
DrugBank: Oxygen (DB09140)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100% oxygen (O2) for inhalation, given at 80ppm over 10 minutes using an INOvent® delivery system
Study: NCT03827668
Drug: PF-06650833 alone
Normalized name: PF-06650833
DrugBank: PF-06650833 (DB15143)
Approvals — FDA: no, EMA: no, PMDA: no
Description: In Period 1, Days 1-5, participants will receive PF-06650833 once daily alone.
Study: NCT03827668
Drug: PF-06651600 alone
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: In Period 2, Days 1-7, participants will receive PF-06651600 once daily alone.
Study: NCT03827668
Drug: PF-06650833 together with PF-06651600
Normalized name: PF-06650833
DrugBank: PF-06650833 (DB15143)
Approvals — FDA: no, EMA: no, PMDA: no
Description: In Period 2, Days 8-12, participants will receive PF-06650833 once daily together with PF-06650833 once daily.
Study: NCT01353144
Drug: aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: aspirin, 100 mg, qd x 8 weeks
Study: NCT00831779
Drug: Dapagliflozin
Normalized name: Dapagliflozin
DrugBank: Dapagliflozin (DB06292)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tablets, Oral, 5 mg, once daily, 12 weeks
Study: NCT00712868
Drug: Lactic acid
Normalized name: Lactic Acid
DrugBank: Lactic acid (DB04398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Once a day
Study: NCT01109693
Drug: Sertraline
Normalized name: Sertraline
DrugBank: Sertraline (DB01104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sertraline 50 mg/d or 100 mg/d for 6 more weeks
Study: NCT01109693
Drug: Mirtazapine
Normalized name: Mirtazapine
DrugBank: Mirtazapine (DB00370)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Augment with or switch to mirtazapine 15-45 mg/d
Study: NCT01156779
Drug: SR-exenatide
Normalized name: Peg loxenatide
DrugBank: Exenatide (DB01276)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Emulsion 0.5mg,1mg,2mg,4mg dosage (Dose-escalation) Single injection
Study: NCT01302743
Drug: Group 1: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Group 1: Will receive oral extended-release Metformin 1000 mg once a day for 90 days
Study: NCT01416870
Drug: Casodex 80 mg tablet
DrugBank: Bicalutamide (DB01128)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subject will receive single dose of Casodex 80 mg tablet
Study: NCT01602887
Drug: PD-0332991
Normalized name: dolutegravir
DrugBank: Dolutegravir (DB08930)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: isethionate hard capsule, 125 mg, single dose
Study: NCT01602887
Drug: PD-0332991
Normalized name: dolutegravir
DrugBank: Dolutegravir (DB08930)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: freebase hard capsule with a small particle size, 125 mg, single dose
Study: NCT01602887
Drug: PD-0332991
Normalized name: dolutegravir
DrugBank: Dolutegravir (DB08930)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: freebase hard capsule with a large particle size, 125 mg, single dose
Study: NCT01602887
Drug: PD-0332991
Normalized name: dolutegravir
DrugBank: Dolutegravir (DB08930)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: oral solution, 50 mg, single dose
Study: NCT00696748
Drug: Nebido (testosterone undecanoate)
Normalized name: Testosterone Undecanoate
DrugBank: Testosterone (DB00624)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nebido (testosterone undecanoate) intramuscular 4 ml by scheme
Study: NCT02506842
Drug: nab-paclitaxel
Normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients firstly receive nab-paclitaxel 100 mg/m\^2 (iv, 30 minutes) on days 1, 8, and 15 for 3 weeks, followed by one week without treatment. Treatment repeats until there is disease progression or recurrence.
Study: NCT02506842
Drug: gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients secondly receive gemcitabine 1000 mg/m\^2 (iv, 30 minutes) on days 1, 8, and 15 for 3 weeks, followed by one week without treatment. Treatment repeats until there is disease progression or recurrence.
Study: NCT02506842
Drug: oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients receive oxaliplatin 85 mg/m\^2 (iv, 2 hours) on days 8 and 22 with 42 days as a cycle. Treatment repeats until there is disease progression or recurrence. Oxaliplatin is given before folinic acid and fluorouracil when the three drugs are given on the same days.
Study: NCT02506842
Drug: folinic acid
Normalized name: Folinic acid
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients receive folinic acid 200 mg/m\^2 (iv) on days 1, 8, 15 and 22 for 4 weeks, followed by 2 weeks without treatment. Treatment repeats until there is disease progression or recurrence.
Study: NCT01982240
Drug: Plecanatide
Normalized name: Plecanatide
DrugBank: Plecanatide (DB13170)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Plecanatide tablets QD for 12 weeks
Study: NCT01982240
Drug: Bisacodyl
Normalized name: Bisacodyl
DrugBank: Bisacodyl (DB09020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rescue medication
Study: NCT04530448
Drug: Sodium bicarbonate
Normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium bicarbonate 225 mEq (225 mL of an 8.4% solution) intravenously over 1 hour. Sodium bicarbonate 8.4% solution should not exceed 900 ml (4 boluses) in 24 hours.
Study: NCT05088070
Drug: SPH 3348
Normalized name: SPH-3127
DrugBank: SPH-3127 (DB19108)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 tablets of 8mg SPH3348 will be orally administered once a day with empty stomach
Study: NCT05088070
Drug: SPH 3348
Normalized name: SPH-3127
DrugBank: SPH-3127 (DB19108)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet of 40mg SPH3348 will be orally administered once a day with empty stomach
Study: NCT05088070
Drug: SPH 3348
Normalized name: SPH-3127
DrugBank: SPH-3127 (DB19108)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 tablets of 40mg SPH3348 will be orally administered once a day with empty stomach
Study: NCT05088070
Drug: SPH 3348
Normalized name: SPH-3127
DrugBank: SPH-3127 (DB19108)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 tablets of 40mg SPH3348 will be orally administered once a day with empty stomach
Study: NCT05088070
Drug: SPH 3348
Normalized name: SPH-3127
DrugBank: SPH-3127 (DB19108)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 tablets of 40mg SPH3348 will be orally administered once a day with empty stomach
Study: NCT05088070
Drug: SPH 3348
Normalized name: SPH-3127
DrugBank: SPH-3127 (DB19108)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 tablets of 40mg SPH3348 will be orally administered once a day with empty stomach
Study: NCT02384759
Drug: aflibercept
Normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT03224585
Drug: Anakinra
Normalized name: ANAKINRA
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Period 1 (Time 0-72 hours) - this will be an open-label phase during which all subjects meeting enrollment criteria will receive anakinra 100 mg subcutaneously injections daily for 3 days.~Period 2 (Time 72 hours to 7 days) - anakinra 100 mg subcutaneous injections daily for 4 days
Study: NCT02267226
Drug: Octafibrin
DrugBank: Fibrin (DB16604)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01223326
Drug: Acetylcysteine (NAC)
Normalized name: Acetylcysteine
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: NAC 150 mg/Kg; and infusion of 50 mg/kg, from 30 minutes before the ischemia up to 60 minutes later to the reperfusion
Study: NCT01223326
Drug: Saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Na Cl 0.9% infusion
Study: NCT03674658
Drug: Propafenone
Normalized name: Propafenone
DrugBank: Propafenone (DB01182)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral, TID
Study: NCT03574428
Drug: GNbAC1
Normalized name: Immunoglobulin G4, anti-(multiple sclerosis-associated retrovirus viral envelope protein) (human-mus musculus monoclonal gnbac1 heavy chain), disulfide with human-mus musculus monoclonal gnbac1 kappa-chain, dimer
DrugBank: Temelimab (DB15634)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monoclonal Antibody infused i.v.
Study: NCT03434418
Drug: osimertinib
Normalized name: Osimertinib
DrugBank: Osimertinib (DB09330)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 80 mg oral administration daily
Study: NCT03706300
Drug: Guaifenesin and Pseudoephedrine Hydrochloride Extended Release Tablets 1200/120 mg
DrugBank: Pseudoephedrine (DB00852)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02095509
Drug: Enoxaparin
Normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug class: Low-molecular weight heparin
Study: NCT01722435
Drug: Opiate Substitution Treatment
Normalized name: hydroxypropyl cellulose, low substituted
DrugBank: Hydroxypropyl cellulose (DB00840)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01992562
Drug: Ziconotide
Normalized name: Ziconotide
DrugBank: Ziconotide (DB06283)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02153060
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone was given at a dose of 40 mg,daily for 4 consecutive days
Study: NCT02153060
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone was given at a dose of 20 mg,daily for 4 consecutive days
Study: NCT00250185
Drug: Sodium Nitrate
Normalized name: Sodium Nitrate
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01753401
Drug: Acthar
Normalized name: Acthar
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acthar is given by subcutaneous (SC) injection (shot under the skin), at a dose of 40 units daily or 80 units every other day
Study: NCT02309515
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT04150172
Drug: Rebamipide SR 150mg
Normalized name: Rebamipide
DrugBank: Rebamipide (DB11656)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Test drug
Study: NCT04150172
Drug: Rebamipide IR 100mg
Normalized name: Rebamipide
DrugBank: Rebamipide (DB11656)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Reference Drug
Study: NCT00316238
Drug: olanzapine-RAIM
Normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02942017
Drug: SAGE-547 90 μg/kg/h
DrugBank: Sage (DB10982)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of SAGE-547
Study: NCT02691923
Drug: Fluorescein
Normalized name: Fluorescein
DrugBank: Fluorescein (DB00693)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02691923
Drug: Fluorescein + ALA
Normalized name: Fluorescein
DrugBank: Fluorescein (DB00693)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01157793
Drug: r-hGH
Normalized name: pantolactone, (R)-
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: r-hGH at a dose of 0.15-1.00 mg/day administered for 48 weeks by s.c. route
Study: NCT01157793
Drug: r-hGH
Normalized name: pantolactone, (R)-
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initially no treatment for the first 24 weeks followed by administration of r-hGH at a dose of 0.15 1.00 mg/day for the next 24 weeks, by s.c. route
Study: NCT04405245
Drug: Latanoprost ophthalmic solution
Normalized name: Latanoprost Ophthalmic Solution
DrugBank: Latanoprost (DB00654)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Latanoprost opthalmic solution to be dosed once daily
Study: NCT02088177
Drug: Long-acting injectable naltrexone
DrugBank: Naltrexone (DB00704)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vivitrol is a long-acting opioid antagonist which blocks opioid agonists from binding at opioid receptors. It be administered as described above.
Study: NCT02825212
Drug: Harvoni
Normalized name: Harvoni
DrugBank: Sofosbuvir (DB08934)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 12 weeks for naïve subjects or non-cirrhotic treatment experienced subjects; or 24 weeks for treatment experienced subjects with cirrhosis
Study: NCT01847456
Drug: human insulin as nasal spray
Normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02825212
Drug: Epclusa
Normalized name: Epclusa
DrugBank: Sofosbuvir (DB08934)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: once daily for 12 weeks (naïve subjects, non-cirrhotic treatment experienced or treatment experienced subjects with compensated cirrhosis) for genotype 1-6 subjects.
Study: NCT00011505
Drug: G-CSF
Normalized name: G-CSF
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT01953913
Drug: Afatinib
Normalized name: Afatinib
DrugBank: Afatinib (DB08916)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Patient will receive afatinib once daily
Study: NCT03469323
Drug: Succinylcholine
Normalized name: Succinylcholine
DrugBank: Succinylcholine (DB00202)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Giving mini-dose succinylcholine to facilitate lung collapse during nonintubated VATS.
Study: NCT02703350
Drug: Insulin Lispro
Normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered SC
Study: NCT00345982
Drug: Serdolect
Normalized name: Serdolect
DrugBank: Sertindole (DB06144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16 mg, 12 weeks
Study: NCT01618162
Drug: insulin degludec/liraglutide
Normalized name: INSULIN DEGLUDEC/LIRAGLUTIDE
DrugBank: Liraglutide (DB06655)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Injected subcutaneously (under the skin) once daily. Dose individually adjusted.
Study: NCT04229836
Drug: Tildrakizumab 100 mg Solution for Injection
DrugBank: Tildrakizumab (DB14004)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will be treated with tildrakizumab 100 mg.
Study: NCT01189279
Drug: bimatoprost Formulation A
Normalized name: Bimatoprost
DrugBank: Bimatoprost (DB00905)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: bimatoprost Formulation A applied topically to the scalp once daily on Day 1 and Days 4-17.
Study: NCT01189279
Drug: bimatoprost Formulation B
Normalized name: Bimatoprost
DrugBank: Bimatoprost (DB00905)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: bimatoprost Formulation B applied topically to the scalp once daily on Day 1 and Days 4-17.
Study: NCT00005014
Drug: Risperidone
Normalized name: Risperidone
DrugBank: Risperidone (DB00734)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT01189279
Drug: bimatoprost Formulation C
Normalized name: Bimatoprost
DrugBank: Bimatoprost (DB00905)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: bimatoprost Formulation C applied topically to the scalp once daily on Day 1 and Days 4-17.
Study: NCT01523054
Drug: Metoprolol- Toprol XL
Normalized name: metoprolol Extended Release Oral Tablet [Toprol]
DrugBank: Metoprolol (DB00264)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extended release tablet, 200mg once daily for 4 days
Study: NCT01523054
Drug: Metoprolol- Lopressor
Normalized name: metoprolol Oral Tablet [Lopressor]
DrugBank: Metoprolol (DB00264)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Immediate release tablet, Day 1 50 mg four times daily, Day 2, 3 and 4 100 mg twice daily
Study: NCT04557072
Drug: Selective alpha-1-antagonist
Normalized name: alpha 1-antitrypsin
DrugBank: Alpha-1-proteinase inhibitor (DB00058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients treated with selective alpha-blockade (prazosin, terazosin, doxazosin)
Study: NCT04557072
Drug: Non-selective alpha-1-antagonist
Normalized name: alpha 1-antitrypsin
DrugBank: Alpha-1-proteinase inhibitor (DB00058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients treated with non-selective alpha-blockade (phenoxybenzamine)
Study: NCT01487811
Drug: biphasic insulin aspart 30
Normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Single dose administrated subcutaneously (s.c., under the skin)
Study: NCT00338884
Drug: Sunitinib malate
Normalized name: Sunitinib Malate
DrugBank: Sunitinib (DB01268)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sunitinib malate starting dose 37.5 mg daily continuous daily schedule
Study: NCT02750254
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02750254
Drug: Busulfan
Normalized name: Busulfan
DrugBank: Busulfan (DB01008)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02750254
Drug: Melphalan
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02750254
Drug: Granulocyte-colony stimulating factor
Normalized name: Granulocyte colony-stimulating factor pegfilgrastim
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02750254
Drug: Azacitidine
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes